The introduction of agents that inhibit tumor angiogenesis by targeting vascular endothelial
growth factor (VEGF) signaling has made a significant impact on the survival of patients with …

Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …

Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …

Sunitinib is one of the most widely used targeted therapeutics for renal cell carcinoma
(RCC), but acquired resistance against targeted therapies remains a major clinical …

What's known on the subject? and What does the study add? Although there have been a
few studies investigating the molecular mechanism mediating the acquisition of resistance to …

Sunitinib is an orally‐administered, multitargeted tyrosine kinase inhibitor. The main targets
are vascular endothelial growth factor receptor (VEGFR)‐1, VEGFR‐2, VEGFR‐3, platelet …

Sunitinib is considered a first-line therapeutic option for patients with advanced clear cell
renal cell carcinoma (ccRCC). Despite sunitinib's clinical efficacy, patients eventually …

Targeted therapy has radically altered the way metastatic renal cancer is treated. Six drugs
are now licensed in this setting, with several other agents under evaluation. Sunitinib is …

The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell
renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients …

As a multitargeted kinase inhibitor, sunitinib has carved its way into demonstrating itself as a
most effective tyrosine kinase inhibitor in the treatment of metastatic renal cell carcinoma …